Acetylation of c-Myc at Lysine 148 Protects Neurons After Ischemia.
Valeria GuzenkoS S BachurinValentina A DzreyanAndrey M KhaitinKalyuzhnaya Y NDemyanenko S VPublished in: Neuromolecular medicine (2024)
This study focuses on understanding the role of c-Myc, a cancer-associated transcription factor, in the penumbra following ischemic stroke. While its involvement in cell death and survival is recognized, its post-translational modifications, particularly acetylation, remain understudied in ischemia models. Investigating these modifications could have significant clinical implications for controlling c-Myc activity in the central nervous system. Although previous studies on c-Myc acetylation have been limited to non-neuronal cells, our research examines its expression in perifocal cells during stroke recovery to explore regulatory mechanisms via acetylation. We found that in peri-infarct neurons, c-Myc is upregulated with acetylation at K148 but not K323 during the acute phase of stroke, with SIRT2 deacetylase primarily affecting K148 acetylation. Molecular dynamics simulations suggest that lysine 148 plays a crucial role in stabilizing c-Myc spatial structure. Increased acetylation at K148 reduces c-Myc compaction, potentially limiting its nuclear penetration, promoting calpain-mediated cleavage, and decreasing nuclear localization. Additionally, cytoplasmic acetylation at K148 may alter c-Myc's interaction with unidentified proteins, potentially influencing its pro-apoptotic effects and promoting cytoplasmic accumulation. Targeting SIRT2 with selective inhibitors could be a promising avenue for future stroke therapy strategies.
Keyphrases
- cell death
- histone deacetylase
- atrial fibrillation
- molecular dynamics simulations
- cell cycle arrest
- transcription factor
- induced apoptosis
- poor prognosis
- oxidative stress
- spinal cord
- stem cells
- cell proliferation
- dna binding
- cerebral ischemia
- molecular docking
- bone marrow
- signaling pathway
- pi k akt
- mesenchymal stem cells
- current status
- cancer therapy
- percutaneous coronary intervention
- smoking cessation
- cell therapy